

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

https://marketpublishers.com/r/CCBFB3610E8EN.html

Date: February 2015

Pages: 64

Price: US\$ 390.00 (Single User License)

ID: CCBFB3610E8EN

Abstracts

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


Roche reported 2014 global sales of its Her2 antibody franchise consisting of Herceptin, Perjeta and Kadcyla, of US\$ 8.3 bln, an increase of about 10% compared with sales of the previous year. The new Her2 antibodies not only should add sales, but importantly contribute to a change of the standard of care of breast cancer with conversion of Herceptin sales of PErjeta and Kadcyla sales as a major line of defence against the forthcoming biosimilar Herceptin launches starting in 2016/2017. However, in 2014 Herceptin sales were still growing with a 7 % increase compared with the previous year and make out about 81% of the franchise sale.

Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments, but also for biosuperior Her2 antibodies based on biparatopic and bispecific antibodies as well as Her2 antibodies with higher antitumor activities, e.g. by redirecting T cells, conferring cytotoxic paylods or radioisotopes.

The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition,



the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies. Competitor projects are listed in a tabular format providing information on:



About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



Contents

Marketed Her2 Antibodies:

Herceptin Sales & Pipeline Perjeta Sales & Pipeline Kadcyla Sales & Pipeline

Trastuzumab Biosuperiors:

Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Other Her2 Antibodies

Herceptin Biosimilars

Corporate Her2 Antibody Biosimilar & Biosuperior Pipelines



I would like to order

Product name: Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin

Product link: https://marketpublishers.com/r/CCBFB3610E8EN.html

Price: US\$ 390.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CCBFB3610E8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970